Abstract
In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 137-144 |
Number of pages | 8 |
Journal | Pharmacogenomics |
Volume | 22 |
Issue number | 3 |
DOIs | |
State | Published - Feb 2021 |
Keywords
- Veterans Affairs
- clinical program
- pharmacogenetics
- pharmacogenomics
- precision medicine
- veterans
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmacology